BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Kinase suppressor of ras 2 (KSR2)

...Cancer INDICATION: Cancer In vitro and cell culture studies identified a small molecule KSR2 stabilizer that...
...screen of kinase inhibitors in a KSR2 binding assay identified a compound that competitively bound KSR2...
...with V600 BRAF mutations, and in preclinical testing for B-cell acute lymphoblastic leukemia (ALL). TARGET/MARKER/PATHWAY: Kinase suppressor of ras 2 (KSR2)...
BioCentury | Dec 3, 2009
Distillery Techniques

Technology: Disease models

...models Ksr2-deficient mice could serve as models to help guide development of new obesity therapies. Ksr2-deficient...
...resistant to insulin and had greater adiposity compared with controls that had functional Ksr2. The Ksr2-deficient...
...and hyperactive compared with the same controls. Next steps include additional studies to understand how KSR2...
BioCentury | May 1, 2007
Politics & Policy

Supreme Court rules on patent obviousness

The U.S. Supreme Court made a decision that could raise the bar for obtaining and defending a patent that combines two or more known elements. On Monday, the court ruled in KSR International Co. v....
BioCentury | Mar 19, 2007
Strategy

Illumina's line in the sand

Illumina Inc. said a jury's decision that the company infringes five patents held by fellow microarray competitor Affymetrix Inc. is a mere bump in the road, as the disputed products in the suit are based...
Items per page:
1 - 4 of 4